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1. Introduction 
Parkinson’s disease (PD) was first described in 1817 by James Parkinson, who described in 
his monograph entitled “An Essay on the Shaking Palsy“ the description of the clinical 
features of this disease (Parkinson, 1817). The cardinal clinical manifestations of PD are 
resting tremor, rigidity, bradykinesia, and gait dysfunction. It is now appreciated that PD is 
also associated with many nonmotor features, including autonomic dysfunction, pain and 
sensory disturbances, mood disorders, sleep impairment, and dementia (Olanow et al, 2009).  
PD is the second most common neurodegenerative disorder, with an average age at onset of 
about 60 years and the mean duration of the disease from diagnosis to death is 15 years, 
with a mortality ratio of 2 to 1 (Katzenschlager et al, 2008). The incidence of the disease rises 
steeply with age, from 17 - 4 in 100 000 person years between 50 and 59 years of age to 93 - 1 
in 100 000 person years between 70 and 79 years, with a lifetime risk of developing the 
disease of 1 - 5% (De Rijk et al, 1995). With the aging of the population and the substantial 
increase in the number of at-risk individuals older than 60 years, it is anticipated that the 
prevalence of PD will increase dramatically in the coming decades (De Lau and Breteler, 
2006).  
The etiology remains obscure but important genetic and pathological clues have recently 
been found. This monograph is designed to make a comprehensive review of all aspects of 
both clinical as pathophysiological and therapeutic concerning PD, as well as an update on 
the innovative aspects of the disease primarily focused on identifying new genetic factors 
and new outlook therapeutics. 
2. Neuropathology 
Pathologically, PD is characterized by degeneration of dopaminergic neurons in the 
substantia nigra pars compacta (SNc). However, cell loss in the locus coeruleus, dorsal 
nuclei of the vagus, raphe nuclei, nucleus basalis of Meynert, and some other 
catecholaminergic brain stem structures including the ventrotegmental area also exists 
(Damier et al, 1999). This nerve-cell loss is accompanied by three distinctive intraneuronal 
inclusions: the Lewy body, the pale body, and the Lewy neurite. A constant proportion of 
nigral neurons (3–4%) contain Lewy bodies, irrespective of disease duration. This finding is 
consistent with the notion that Lewy bodies are continuously forming and disappearing in 
the diseased substantia nigra (Greffard et al, 2010). The brain-stem shape is a spherical 
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structure measuring 8–30μm with a hyaline core surrounded by a peripheral pale-staining 
halo, and is composed ultrastructurally of 7–20-nm wide filaments with dense granular 
material and vesicular structures. Pale bodies are large rounded eosinophilic structures that 
often displace neuromelanin and are the predecessor of the Lewy body. 
Aggregated α-synuclein is the main component of Lewy bodies in dopaminergic neurons of 
all PD patients, including those in whom PD occurred sporadically. Aggregated α-synuclein 
in the cytosol of cells does not only occur in the Substantia nigra but already earlier, pre-
symptomatically in the motor part of the Nucleus vagus, in the olfactory bulb and in the 
Locus coeruleus. In later stages cortical areas of the brain are also frequently involved (Braak 
and Tredici, 2010). In fact, these bodies are present in small numbers in almost all cases of 
PD (Halliday et al, 2008). Neocortical Lewy bodies are not necessarily the pathological 
correlate of dementia in PD (Colosimo et al, 2003; Parkkinen et al, 2005). The amount of 
associated cortical β-amyloid seems to be the key factor for the cognitive decline in PD 
(Holton et al, 2008; Halliday et al, 2008). The hypothesis that the aggregation of α-synuclein 
and the build up of Lewy bodies results in toxicity has been challenged.  
Currently, most evidence indicates that oligomers but not the fibrils of α-synuclein that are 
deposited in the Lewy bodies, are the toxic species. This would also imply that the rapid 
conversion of α-synuclein from an oligomeric to an aggregated state, deposited in Lewy 
bodies, may help to detoxify the oligomeric form of α-synuclein (Goldberg and Lansbury, 
2000). Fetal mesencephalic neurons implanted in patients with PD to restore dopaminergic 
transmission may develop Lewy bodies. The existence of different striatal level factors present 
in the striatal microenvironment of the host probably triggers the propagation of alpha- α-
synuclein pathology. Inflammation, oxidative stress, excitotoxicity, and loss of neurotrophic 
support of the grafted neurons could all be important factors (Li et al, 2008, 2010). A prion 
hypothesis implicating permissive templating has also been proposed (Hardy 2005). 
The few patients with PD of genetic origin (α-synuclein, LRRK-2, and GBA mutations) who 
have had autopsy have all shown changes indistinguishable from those found in patients 
with PD (Lees et al, 2008). Some families with LRRK-2 mutations also have tangle pathology 
and non-specific neuronal loss (Gilks et al, 2005). In contrast, parkin mutations lead to nigral 
loss, restricted brain-stem neuronal loss, and absence of associated Lewy bodies or 
neurofibrillary degeneration. Heterozygous parkin carriers, however, have been associated 
with both Lewy body and neurofibrillary tangle pathology (Van de Warrenburg et al, 2001; 
Pramstaller et al, 2005). 
3. Genetic of Parkinson’s disease 
The PD is mostly idiopathic. However, at present, genetics has taken a very important role 
in clinical diagnosis. The first genetic contribution to PD was made by William Richard 
Gowers, in 1902, with the observation of familial aggregation in some patients with PD, but 
it was not until 1997 that discovered the first gene mutation associated with it (SNCA/α–
synuclein). 
Today there are two kinds of Mendelian PD: autosomal dominant and autosomal recessive 
PD. Generally, the recessive autosomal forms are associated with PD onset age of juvenile 
(age of onset <40 years) and an unknown condition. Parkin (PRKN) is the most frequently 
mutated gene in early-onset PD. Dominant autosomal PD is later onset, usually appears 
between 50-60 years of age, and pathologically with Lewy bodies. LRRK2 is the most 
frequently mutated gene in dominant PD (Lees et al, 2009). 
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Mutations in the glucocerebrosidase gene (GBA) are associated with Gaucher’s disease, the 
most common lysosomal storage disorder. Parkinsonism is an established feature of 
Gaucher’s disease and an increased frequency of mutations in GBA has been reported in 
several different ethnic series with sporadic PD. Heterozygous mutations in the GBA gene 
significantly increased (five times) the risk of PD (Sidransky et al, 2009). In addition, patients 
with heterozygous mutations in the GBA gene also have pathology similar to idiopathic PD, 
with the presence of Lewy bodies and α-synuclein aggregate. GBA mutations represent a 
significant risk factor for the development of PD and suggest that to date, this is the most 
common genetic factor identified for the disease (Neumann et al, 2009). 
3.1 Autosomal dominant forms of Parkinson's disease 
To date, there are two genes associated with dominant autosomal dominant PD: SNCA/α-
synuclein (PARK1) and leucine rich repeat kinase 2 (LRRK2, PARK8). 
3.1.1 SNCA/α-synuclein (PARK1) 
SNCA located on chromosome 4q21 (PARK1) was the first gene associated with PD. First, 
mutations in this gene were identified in families of Greek and Italian origin in 1997 
(Polymeropoulos et al, 1997). This discovery was very important, because the identification 
of mutations in this gene was the first evidence that PD could be due to a genetic cause. 
After the discovery of the first pathogenic mutation, p.Ala53Thr (Polymeropoulos et al, 
1997), two mutations were identified in the SNCA gene: mutation in a German family 
p.Ala30Pro (Kruger et al, 1998) and p.Glu46Lys mutation in a Spanish family (Zarranz et al, 
2004). Years later, in 2003, was discovered the first affecting the genomic triplication of 
SNCA locus in a large family with PD (known as the 'Iowa kindred') (Singleton et al, 2003). 
After identification of the SNCA triplication, duplication SNCA genomic locus have also 
been identified in familial and sporadic forms of PD (Chartier-Harlin et al, 2004). 
The SNCA gene encodes a protein called α-synuclein. This protein consists of 140 amino 
acids and is highly expressed in the central nervous system. α-Synuclein is the major 
fibrillar component of the Lewy body (Spillantini et al, 1997). Although its function is still 
unknown, appears to be involved in synaptic plasticity, neuronal differentiation, and axonal 
transport and synaptic vesicles (Biskup et al, 2008). 
Symptoms caused by mutations in the SNCA gene are variable, but usually comes with age 
at onset around 50 years and phenotypic characteristics common to Lewy body dementia, 
with deposits of α-synuclein fibril and / or protein Tau, where Lewy bodies are more 
distributed throughout the brain of what we usually see in the PD. Some patients have 
dementia, visual hallucinations, parkinsonism and fluctuating cognition and attention (for 
example, patients with the mutation p.Glu46Lys and SNCA locus triplication). In contrast, 
the families described with duplication of the SNCA locus appear to have a slower 
progression of the disease, age of onset is usually late and not have dementia (Hardy et al, 
2009). These latter observations led to suggest that the evolution of the disease may be 
associated with a dose-related effect of the SNCA locus (Singleton et al, 2003). 
3.1.2 LRRK2/Dardarin (PARK 8) 
Another locus for a dominant form of PD was first mapped in a Japanese family on 
chromosome 12 and named PARK8 (Funayama et al, 2002). Missense mutations in the gene 
for LRRK2 were found to be disease causing in 2004 (Paisan-Ruiz et al, 2004; Zimprich et al, 
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2004). The most common mutation is the p.Gly2019Ser, which also constitutes the most 
common mutation of both mendelian and sporadic PD (Healy et al, 2008). Although there 
are over 50 different mutations described in the gene for confirmation dardarin 
pathogenicity in some of these mutations are difficult (Paisán-Ruiz 2009). 
LRRK2 contains 51 coding exons and encodes a protein of 2,257 amino acids called dardarin. 
Endogenous LRRK2 is ubiquitiously expressed within neurons and associates with 
membranes and lipid rafts. The protein is found in presynaptic terminals where it associates 
with vesicles and endosomes (Biskup et al, 2008). Its function remains unknown, although 
functional studies have found that certain mutants alter LRRK2 kinase activity and this 
activity is crucial for the toxic effect of the protein. It has also been seen that certain LRRK2 
gene mutations cause neuronal death (Biskup et al, 2008). It is also believed that dardarin 
could be involved in vesicular traffic system (Shin et al, 2008).  
Mutations in the LRRK2 gene vary greatly depending on the patient's geographical origin. 
There is some ethnic influence in the changes associated with the gene LRRK2. 
p.Arg1628Pro and p.Gly2385Arg as mutations, which, being absent in the Caucasian 
population, significantly increase the risk of PD in Asian populations. Both mutations are 
present in the normal population with a frequency of 2.65% (p.Arg1628Pro) and 1.8% 
(p.Gly2385Arg), but its prevalence is significantly higher in patients with PD. In addition, 
the mutation p.Gly2019Ser, common in the Caucasian population, is rarely identified in the 
Asian population (<0.1%), however, two mutations adjacent to amino p.Gly2019, 
p.Ile2012Thr and p.Ile2020Thr, occur more frequently in Asians than in Caucasians (Paisán-
Ruiz 2009). 
The clinical presentation closely resembles sporadicPD, but patients tend to have a slightly 
more benign course and are less likely to develop dementia and a favorable response to 
treatment with levodopa. Unilateral tremor is usually the first symptom of the disease, 
progressing slowly and benign. Patients with mutations in the LRRK2 gene are prone to 
develop dystonia (Healy et al, 2008). The age of onset is very variable (from 28 to 90 years 
old), but with an average age approaching 60 years. A person who inherits the Gly2019Ser 
mutation has only 28% risk of developing parkinsonism when younger than 60 years of age, 
but the risk rises to 74% at 79 years of age (Paisán-Ruiz 2009). p.Gly2019Ser mutation 
carriers have been described with no parkinsonian symptoms, suggesting the existence of 
incomplete penetrance associated with this mutation, and homozygous carriers without 
additional clinical effect caused by gene dosage (Paisán-Ruiz 2009). 
3.2 Autosomal recessive forms of Parkinson's disease 
Loss-of-function mutations in four genes (PRKN, DJ-1, PINK1, and ATP13A2) cause early 
onset recessive parkinsonism (age of onset <40 years). Parkin mutations are the second most 
common genetic cause of L-dopa-responsive parkinsonism, whereas mutations in the other 
three genes are rare. 
3.2.1 PRKN/parkin (PARK2) 
The PARK2 locus was cloned by extensive linkage analysis conducted in 13 consanguineous 
families from Japan in 1997. Today, mutations (> 100 different mutations) in the PRKN gene 
are the most common genetic cause of early-onset parkinsonism (onset age <40 years). The 
clinical picture associated with mutations in this gene is also similar to idiopathic PD, with a 
slow disease progression and response generally appropiate to treatment with levodopa. 
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Patients often develop dyskinesias at low doses of levodopa and generally develop 
dystonia. Lewy bodies are usually not a common pathology (Khan et al, 2003). 
Parkin protein localizes, although not predominantly, to the synapse and associates with 
membranes. In general parkin is a cytoplasmic protein and functions in the cellular 
ubiquitination/ protein degradation pathway as an ubiquitin ligase (Kubo et al, 2001). 
3.2.2 PINK1/PTEN-induced putative kinase 1(PARK6) 
Initially, the PARK6 locus was cloned in a large Sicilian family in 2001. Three years later, 
pathogenic mutations in a gene called PINK1 were identified in several Italian families 
(Valente et al, 2004). Symptoms caused by this gene are very similar to that described in 
patients with mutations in the PRKN gene. However, the age of onset may be more variable, 
reaching present even at 68 years of age, but typically has a juvenile onset (Kumazawa et al, 
2008). 
PINK1 encodes a primarily mitochondrial protein kinase. Mutations in the PINK1-gene are 
much less common than parkin mutations, and probably account for only 1 to 4 % of early-
onset cases (Valente et al, 2004; Kumazawa et al, 2008; Rogaeva et al, 2004). 
3.2.3 DJ-1 (PARK7) 
Mutations in the DJ-1 gene (PARK7) are another rare cause of recessive autosomal 
parkinsonism (Bonifati et al, 2003; Hedrich et al, 2004). The clinical picture with early-onset 
and slow progression is similar to other recessive autosomal forms of PD. The normal 
function of DJ-1 and its role in dopamine cell degeneration is unknown, but there is 
evidence linking DJ-1 to oxidative stress response and mitochondrial function (Hardy et al, 
2009). 
3.2.4 ATP13A2-5P-type ATPase (PARK9) 
The locus PARK9, ATP13A2 was first identified in families of Chilean and Jordanian origin 
who had a syndrome known as Kufor-Rakeb. This disease is rare and presents with a rigid 
and akinetic parkinsonism and juvenile onset. Spasticity, Babinski signs, supranuclear gaze 
palsy and cognitive impairment are some of the clinical symptoms that often occur in this 
disease (Paisán-Ruiz et al, 2010). The gene encodes a protein lysosomal of 1,180 amino acids 
that are abundantly expressed in the brain and might act in the proteolytic degradation 
carried out in the lysosomes (Ramirez et al, 2006). 
3.2.5 Other autosomal recessive forms of parkinsonism 
Recently, mutations in the gene PLA2G6 (phospholipaseA2 calcium-independent)(PARK 14) 
were also found present in individuals who had an akinetic and progressive parkinsonism. 
Cognitive impairment is a clinical symptom that often accompanies these patients. PLA2G6 
encodes a phospholipase enzyme of 752 amino acids. In general, the phospholipases induce 
changes in the composition of the membrane, activate the inflammatory cascade and alter 
cell signaling pathways of unknown function (Paisán-Ruiz et al, 2010). 
Several familial cases with a complex parkinsonism and dystonia have been identified with 
mutations in the gene FBX07 (PARK15). The clinical features resembling parkinsonism 
caused by mutations in the PRKN gene. In fact, FBXO7 gene encodes a protein of 522 amino 
acids, which seems to be also involved in the system of ubiquitin-proteasome protein 
degradation (Di Fonzo et al, 2009; Paisán-Ruiz et al, 2010). 
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Recently, it has been shown that patients with mutations in the gene spatacsin (SPG11) (Non 
PARK locus) develop a juvenile parkinsonism similar to that caused by genes ATP13A2, 
PLA2G6 and FBX07. These patients show a thinning of the corpus callosum, very 
characteristic signs of spastic paraplegia. The presenting symptoms of the disease are often 
both spasticity and parkinsonism (Paisán-Ruiz et al, 2010). 
4. Clinical features 
PD commonly presents with impairment of dexterity or, less commonly, with a slight 
dragging of one foot. The onset is gradual and the earliest symptoms might be unnoticed or 
misinterpreted for a long time. Fatigue and stiffness are common but non-specific 
complaints. Other initial symptoms are lugubrious stiff face, a hangdog appearance, a 
flexion of one arm with lack of swing, a monotonous quality to the speech, and an extreme 
slowing down. The early physical signs are often erroneously and a lag of 2–3 years from 
the first symptoms to diagnosis is not unusual. A change in a patient's writing can be 
present for several years before diagnosis, with a tendency to slope usually in an upward 
direction and for the writing to get progressively smaller and more cramped after a line or 
two (Lee et al, 2009). 
Complaints within the first 2 years of the disease of falls (especially backwards), fainting, 
urinary incontinence, prominent speech, disturbed swallowing, amnesia, or delirium should 
raise the possibility of an alternative diagnosis. 
In the late stages of PD, the face of patients is masked and expressionless, the speech is 
monotonous, festinant, and slightly slurred, and posture is flexed simian with a severe pill 
rolling tremor of the hands. Freezing of gait for several seconds can happen when 
attempting to enter the consulting room and, when starting to move again, the patient tends 
to move all in one piece with a rapid propulsive shuffle. These motor blocks lead to falls. All 
dextrous movements are done slowly and awkwardly, and assistance might be needed for 
dressing, feeding, bathing, getting out of chairs, and turning in bed. Constipation, chewing 
and swallowing difficulties, drooling of saliva, and urge incontinence of urine are common 
complaints. 
Although PD has long been considered primarily a motor disorder Nonmotor symptoms 
(NMS) in PD are common and were recognized by James Parkinson himself. Thus, in his 
Essay on the Shaking Palsy in 1817, he referred to sleep disturbance, constipation, urinary 
incontinence and delirium (Parkinson, 1817). Numerous studies have now indicated that 
NMS is an integral symptom complex of PD, affecting memory, bladder and bowel, and 
sleep among others (Table 1) (Chaudhuri et al, 2006). It is commonly thought that NMS 
occur only in late or advanced PD but NMS can indeed present at any stage of the disease 
including early and pre-motor phase of PD. Several NMS of PD such as olfactory problems, 
constipation, depression and erectile dysfunction may predate the motor signs, symptoms 
and diagnosis of PD by a number of years (Chaudhuri et al, 2006; Tolosa et al, 2007). 
Patients with PD are prone to have sleep disturbances that result in excessive daytime 
somnolence (EDS) and require proper identification and treatment (Comella, 2007). Sleep 
dysfunction in PD is usually manifest by difficulty in initiating sleep, fragmented sleep, 
REM behavior disorder (RBD), reversal of the sleep cycle, and EDS (Porter et al, 2008). It is 
possible that RBD might be early features of PD that antecede the onset of the classic motor 
features of the disease. In fact, in one study, RBD was found to have preceded the onset of 
PD symptoms in 52% of patients (Postuma et al, 2006). RBD in patients with PD is 
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frequently seen in association with visual hallucinations (Meral et al, 2007). The presence of 
RBD in patients with PD is also frequently associated with neuropsychiatric problems and 
cognitive impairment. Even the presence of RBD in a patient with PD without dementia 
predicts the subsequent development of cognitive impairment (Vendette et al, 2007).  
Although, troublesome dysautonomia is recognized in advanced PD, cardiac (123)I-
metaiodobenzylguanidine (MIBG) imaging demonstrates early cardiac sympathetic 
denervation in PD (low cardiac uptake) and not multiple system atrophy (MSA) where the 
heart is usually visualized (Goldstein et al, 2000). Cardiac sympathetic denervation has also 
been found in genetic forms of PD with alpha synuclein mutation (Singleton et al, 2004). 
Neuropsychiatric problems such as dementia, delirium, anxiety, and depression occur at 
one time or another in most patients, and can potentially be more disabling than motor 
dysfunction. 
Risk of dementia exists, particularly in those patients who present with prominent gait and 
speech disorders, depression, and a poor response to L-dopa. The greatest risk factor for 
dementia, however, is the age of the patient and not the duration of the disease (Levy, 2007). 
Visuospatial difficulties, disturbances of attention and vigilance, delirium, and executive 
dysfunction are more common in PD than in Alzheimer's disease (Noe et al, 2004). Visual 
hallucinations are commonly associated with PD dementia. 
Depression is pervasive in PD and affects approximately 40% of patients at least once 
during the course of their disease (Starkstein et al, 1992). Studies have suggested that 
symptoms of depression may precede the development of PD.  
5. Pharmacologic treatment 
5.1 Neuroprotection 
Several putative neuroprotective agents have been tested in placebo-controlled clinical 
trials. Some clinical trials had negative outcomes despite promising theoretical or preclinical 
evidence. These include the antioxidant vitamin E (Parkinson Study Group, 1993), the 
glutamate release inhibitor riluzole (Jankovic and Hunter, 2002) , coenzyme Q10 (Shults et 
al, 2002), glial cell line-derived neurotrophic factor (GDNF) (Nutt et al, 2003), the 
antiapoptotic agents TCH346 (Olanow et al, 2006), CEP-1437 (Parkinson Study Group, 2007), 
and the neuroimmunophilins (Gold and Nutt, 2002) which are thought to act via a possible 
trophic mechanism. Conversely, some putative neuroprotective agents have demonstrated 
significant benefits compared with controls, but still could not be unequivocally deemed to 
be neuroprotective because of the possibility of confounding symptomatic or pharmacologic 
effects. Although it is not possible to claim with certainty that any of these drugs are 
neuroprotective, many are routinely used by physicians based on the hope that they might 
slow disease progression. These agents are considered below. 
5.1.1 Selegiline 
Selegiline is a selective, irreversible inhibitor of monoamine oxidase-B (MAO-B). Selegiline 
was the first drug to be tested as a putative neuroprotective therapy in patients with PD based 
on its capacity to protect dopamine neurons by inhibiting the MAO-B oxidation of MPTP and 
blocking the formation of free radicals derived from the oxidative metabolism of dopamine 
(Olanow 1996). The initial advantages shown by selegiline have not been maintained. 
Furthermore, evidence is insufficient to make a conclusion on the neuroprotective, as opposed 
to the symptomatic effect of selegiline in PD (Parkinson Study Group, 1996).  
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Neuropsychiatric symptoms 
Depression, apathy, anxiety  
Anhedonia 
Attention deficit 
Hallucinations, illusion, delusions 
Dementia 
Obsessional and repetitive behaviour (usually drug induced)  
Confusion 
Delirium (could be drug induced) 
Panic attacks 
Sleep disorders 
Restless legs and periodic limb movements 
REM behaviour disorder and REM loss of atonia 
Non-REM sleep related movement disorders 
Excessive daytime somnolence 
Vivid dreaming 
Insomnia 
Sleep disordered breathing 
Autonomic symptoms 
Bladder disturbances 
Urgency 
Nocturia 
Frequency 
Sweating 
Orthostatic hypotension  
Coat hanger pain 
Sexual dysfunction 
Hypersexuality (likely to be drug induced) 
Erectile impotence 
Dry eyes (xerostomia) 
Gastrointestinal symptoms 
Dribbling of saliva 
Ageusia 
Dysphagia/ choking 
Reflux, vomiting 
Nausea 
Constipation 
Unsatisfactory voiding of bowel 
Fecal incontinence 
Sensory symptoms 
Pain 
Paraesthesia 
Olfactory disturbance 
Other symptoms 
Fatigue 
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Diplopia 
Blurred vision 
Seborrhoea 
Weight loss 
Weight gain (possibly drug induced) 
Table 1. Nonmotor features of PD 
5.1.2 Rasagiline 
Rasagiline is another selective, irreversible MAO-B inhibitor. There are data from studies in 
vitro and in animal models have shown neuroprotective capacity by rasagiline (Sagi et al, 
2007; Zhu et al, 2008). 
To test for a possible neuroprotective effect in patients with PD, rasagilina had been shown 
to have a symptomatic effect in the TEMPO study (The Rasagiline Mesylate in Early 
Monotherapy for PD Outpatients) (Parkinson Study Group, 2002). ADAGIO (the Effect of 
Rasagiline Mesylate in Early PD patients) study was designed to verify these results. It 
demonstrated that early treatment with rasagiline 1 mg daily provided a benefit that was 
not obtained with the delayed introduction of the drug. These results are consistent with 
rasagiline having a possible neuroprotective effect (Olanow et al, 2009). 
5.1.3 Dopamine agonist 
Dopamine agonists have been studied for putative neuroprotective effects in PD, based on 
their capacity to protect dopamine neurons from a variety of toxins (Schapira, 2002). Indeed, 
the dopamine agonist pramipexole has been reported to protect dopamine neurons in 
MPTP-lesioned primates (Iravani et al, 2006). 
Clinical trials have attempted to test the capacity of dopamine agonists to provide disease-
modifying effects in PD. However, Class I randomized, controlled trials with bromocriptine 
(Olanow et al, 1995), pramipexol (Parkinson Study Group, 2000; Parkinson Study Group, 
2002), and ropinirole (Rakshi et al, 2002; Whone et al, 2003) produced no convincing 
evidence of neuroprotection in early PD. 
5.1.4 Levodopa 
The only available placebo-controlled study of levodopa in relation to neuroprotection is 
inconclusive about any Neuroprotective, as opposed to symptomatic effect (Fahn et al, 
2004). Mortality studies suggest improved survival with levodopa therapy (Rajput 2001). 
5.2 Motor symptoms treatment of PD 
5.2.1 Levodopa 
Levodopa is the most effective drug for the symptomatic treatment of PD and the gold 
standard against which new therapies must be measured. Benefits are usually seen in all 
stages of the disease and can be particularly noteworthy in patients with early PD, in whom 
the drug can control virtually all of the classic motor features. Although prediction of the 
therapeutic response in an individual is not possible, motor symptoms initially improve by 
20–70%. Speech, swallowing, and postural instability can improve initially, but axial 
symptoms are generally less responsive and seem to escape more readily from long-term 
control (Fahn et al, 2004). 
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Levodopa exerts its symptomatic benefits through conversion to dopamine, and is routinely 
administered in combination with a decarboxylase inhibitor (carbidopa, benserazide) to 
prevent its peripheral conversion to dopamine and the resultant nausea, vomiting and 
orthostatic hypotension. A combination of carbidopa/levodopa and the COMT inhibitor 
entacapone is available. There are also sustained-release formulations of levodopa although 
sustained-release formulations of levodopa are not as well absorbed as regular formulations, 
and doses 20% to 30% higher may be necessary to achieve the same clinical effect. A gel 
preparation of levodopa (Duodopa) has been used for intraintestinal infusion of the agent 
and is used in more advanced stages of disease. 
Levodopa is absorbed in the small bowel by active transport through the large neutral 
amino acid (LNAA) pathway, and can be impaired by alterations in gastrointestinal motility 
and by dietary LNAAs, such as phenylalanine, leucine, and valine, which compete with 
levodopa for absorption through the LNAA (Nutt et al, 1984). 
Acute side effects associated with levodopa include nausea, vomiting, and hypotension, but 
levodopa is generally well tolerated when it is gradually increased. Levodopa is generally 
started at a low dose to minimize these risks. Most people can be maintained over the first 5 
years of the disease on 300–600 mg/day levodopa. Levodopa maintain a similar level of 
control in de novo PD after 5 years (Koller et al, 1999), and also in more advanced PD with a 
duration of about 10 years and without motor fluctuations(Goetz et al, 1988). 
Chronic levodopa therapy is associated with motor complications, such as dyskinesias and 
motor fluctuations, in the majority of patients. Motor fluctuations include delayed onset of 
levodopa’s therapeutic effect or its wearing off between doses. Dyskinesias are involuntary 
choreiform movements that can involve any part of the body and sometimes impose 
disabling or painful postures. A meta-analysis found 40% likelihood of motor fluctuations 
and dyskinesias after 4–6 years of levodopa therapy (Ahlskog and Muenter, 2001). Risk 
factors are younger age, longer disease duration, and levodopa (Denny AP and Behari M, 
1999; Fahn et al, 2004). In individual studies, the percentage of fluctuations and dyskinesia 
may range from 10% to 60% of patients at 5 years on disease duration, and up to 80–90% in 
later years (Olanow et al, 2001). Patients with PD can also experience fluctuations in such 
nonmotor symptoms as mood, cognition, autonomic disturbances, pain, and sensory 
function (Witjas et al, 2002). Levodopa may also be associated with neuropsychiatric side 
effects, including cognitive impairment, confusion and psychosis. Importantly, many PD 
features are not satisfactorily controlled by, or do not respond to, levodopa. These include 
freezing episodes, postural instability with falling, autonomic dysfunction, mood disorders, 
pain and sensory disturbances, and dementia. Levodopa treatment can also be associated 
with a dopamine dysregulation syndrome in which patients compulsively take extra doses 
of levodopa in an addictive fashion. Although levodopa has been associated with impulse 
control disorders (ICDs) such as hypersexuality and pathologic gambling, these behaviors 
have primarily been reported to be associated with dopamine agonists (Ceravolo et al, 2010). 
In addition, chronic levodopa treatment has been associated with punding, which is a series 
of repetitive and purposeless behaviors, such as collecting or assembling and disassembling 
objects for no apparent reason (Evans et al, 2004).  
There has long been a theoretical concern that levodopa might accelerate neuronal 
degeneration in PD because of the potential of the drug to generate free radicals through its 
oxidative metabolism (Olanow et al, 2004). However, most studies in animal models and 
humans do not show an accelerated loss of dopaminergic neurons to long-term levodopa 
therapy in usual clinical doses (Olanow et al, 2004). The Earlier vs Later Levodopa Therapy 
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in PD (ELLDOPA) study was the first double-blind, placebo-controlled trial to assess the 
safety and efficacy of different doses of levodopa and address the potential toxicity of 
levodopa in patients with PD (Fahn et al, 2004). The clinical results of this study certainly do 
not provide any evidence to suggest that levodopa is toxic or accelerates the development of 
disability in patients with PD and do not demonstrate any adverse effect of levodopa on PD 
progression. 
5.2.2 Dopamine agonist 
Dopamine agonists are a class of drugs with diverse physical and chemical properties. They 
share the capacity to directly stimulate dopamine receptors, presumably because they 
incorporate a dopamine-like moiety within their molecular configuration. Dopamine 
agonists have drawn particular interest as a treatment for PD because of their potential to 
provide antiparkinsonian effects with a reduction in the motor complications associated 
with levodopa. Today, dopamine agonists are also used as early symptomatic therapy to 
reduce the risk of developing the motor complications associated with levodopa therapy. 
It is generally accepted that the shared D2-like receptor agonistic activity produces the 
symptomatic antiparkinsonian effect. This D2 effect also explains peripheral 
(gastrointestinal nausea and vomiting), cardiovascular (orthostatic hypotension) and 
neuropsychiatric (somnolence, psychosis, and hallucinations) side effects. 
The first group of dopamine agonists used in the treatment of PD were ergot derivatives 
(bromocriptine, cabergoline, lisuride, pergolide, dihidroergocriptine). Numerous studies 
have demonstrated the effectiveness of these agents in PD as adjuncts to levodopa and 
shown that as monotherapy they are associated with a reduced risk of inducing dyskinesia 
compared with levodopa (Montastruc et al, 1994; Bracco et al, 2004; Oertel et al, 2006). 
However, their use has markedly declined due to the risk of valvular fibrosis and the 
introduction of nonergot dopamine agonists (apomorfine, pramipexole, ropinirole, 
rotigotine, piribedil). Although rare, cardiac dysfunction with valvular thickening and 
fibrosis has been reported with pergolide and cabergoline, presumably because they activate 
the 5HT2b receptor (Morgan and Sethi 2006; Zanettini et al, 2007; Roth BL 2007). In the 
nineties, nonergot dopamine agonists have largely supplanted the ergot agonists as the 
dopamine agonists of choice for the treatment of PD. Apomorphine is a short-acting 
dopamine agonist that is available in injectable form as a rescue drug for the management of 
“off” periods, and in some countries as an subcutaneous infusion therapy for the 
management of patients with advanced motor complications.  
Levodopa is more efficacious than any orally active dopamine agonist monotherapy. The 
proportion of patients able to remain on agonist monotherapy falls progressively over time 
to <20% after 5 years of treatment. For this reason, after a few years of treatment, most 
patients who start on an agonist will receive levodopa as a replacement or adjunct treatment 
to keep control of motor parkinsonian signs. Over the last decade, a commonly tested 
strategy has been to start with an agonist and to add levodopa later if worsening of 
symptoms cannot be controlled with the agonist alone (Rinne et al, 1998; Parkinson Study 
Group 2000; Rascol et al, 2000).  
From the limited data available (bromocriptine versus ropinirole, bromocriptine versus 
pergolide), the clinical relevance of the reported difference between agonists, if any, remains 
questionable (Mizuno Y et al, 1995; Korczyn et al, 1999). 
Class I randomized, controlled trials demonstrate how early use of an agonist can reduce the 
incidence of motor complications versus levodopa (cabergoline (Bracco et al, 2004), 
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pramipexole (Parkinson Study Group, 2000), and ropinirole (Rascol et al, 2000; Whone et al 
2003). Similar conclusions were reported with bromocriptine (Montastruc et al, 1994), and 
pergolide (Oertel et al, 2006) in several class II studies. There is no evidence to suggest that 
an agonist is more effective than another in preventing or delaying the time to onset of 
motor complications. Dopamine agonists serve to delay the onset of motor complications by 
delaying the time until levodopa is required, but do not prevent motor complications once 
levodopa is introduced. Indeed, two studies have now shown that the time to onset of motor 
complications from when levodopa is introduced is the same whether levodopa is used as 
initial therapy or as an adjunct to the dopamine agonist (Rascol et al, 2000; Constantinescu et 
al, 2007). 
Regarding the treatment of non-motor symptoms in PD pramipexole has shown to have an 
antidepressant effect in several randomized, double-blind controlled studies (Corrigan et al, 
2000; Lemke et al, 2006; Bxarone et al, 2010). A recent study with transdermal rotigotine 24 
hours monotherapy vs placebo has shown an improvement in nocturnal sleep disturbance 
(assessed by the "Modified Parkinson's Disease Sleep Scale) and early-morning motor 
dysfunction (Trenkwalder et al, 2011). 
There are long-acting preparation of pramipexole and ropinirole with 24-hour prolonged 
release. Also rotigotine by transdermal administration has been shown to have constant 
levels of drug with a single patch daily. This allows for less fluctuation in plasma drug 
levels and permits drug levels to be maintained during the waking day and to drop off 
during the night. This may lead to better compliance and more consistent symptom 
response throughout the day and perhaps better nighttime symptom control. In adjunct 
studies, ropinirole (Pahwa et al, 2007) and pramipexol (Hauser et al, 2010) 24 hours 
provided improvement in UPDRS motor and quality-of-life scores comparable with the 
immediate release form of the drug and was well tolerated.  
Dopamine agonists and all other active dopamine-mimetic medications share a common 
safety profile. Accordingly, side effects such as nausea, vomiting, orthostatic hypotension, 
confusion and psychosis, may occur with administration of any of these agents. 
Hallucinations and somnolence are more frequent with some agonists than with levodopa 
and are particularly common in elderly people or patients with cognitive impairment 
(Etminan et al, 2001). The ergot-derived dopamine agonists can be associated with a 
Raynaud’s-like phenomena, erythromelalgia, and pulmonary or retroperitoneal fibrosis 
(Andersohn and Garbe, 2009). These events are relatively uncommon and are not seen with 
the nonergot dopamine agonists. Valvular fibrosis may occur in as many as 30% of patients 
receiving ergot-based dopamine agonists and can lead to valvular dysfunction with the 
need for surgical repair in extreme cases. This has resulted in withdrawal of pergolide from 
the market, and a marked reduction in the use of the other ergot agonists (Zanettini et al, 
2007; Roth 2007). When these agents are used, it is essential that patients be periodically 
monitored with echocardiography to detect valvular alterations. 
Sedation with EDS and possible unwanted sleep episodes has been associated with the use 
of dopamine agonists. Dopaminergic medications and dopamine agonists in particular, are 
known to have dose-related sedative side effects (Frucht et al, 1999; Ferreira et al, 2000; Paus 
et al, 2003). 
Other problems related to the use of dopamine agonists include weight gain (possibly 
related to overeating) (Nireberg and Waters, 2006), edema (especially in the lower 
extremities) (Kleiner-Fisman G and Fisman, 2007) and a variety of ICDs, such as pathologic 
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gambling, hypersexuality, and compulsive eating and shopping (Weintraub et al, 2006). Risk 
factors for ICDs include current use of dopamine agonists, particularly in high doses, young 
age of PD onset, and a premorbid or family history of ICDs or depression (Voon et al, 2006). 
ICDs were first identified in association with pramipexole, but have now been described 
with ropinirole and pergolide. Interestingly, they occur much less frequently with levodopa, 
although punding is primarily associated with chronic levodopa treatment. The precise 
mechanism whereby dopamine agonists might induce these ICDs is not known. It remains 
to be determined if dopamine agonists are directly responsible for inducing an ICD through 
a particular pattern of receptor stimulation, or if there is an underlying personality disorder 
that becomes clinically manifest with restoration of striatal dopaminergic tone. 
5.2.3 Catechol-O-methyltransferase (COMT) inhibitors 
Catechol-O-methyltransferase (COMT) inhibitors reduce the metabolism of levodopa, 
extending its plasma half-life and prolonging the action of each levodopa dose. 
Administration of levodopa with a COMT inhibitor increases its elimination half-life (from 
about 90 minutes to about 3 hours). 
Two COMT inhibitors have been approved as adjuncts to levodopa for the treatment of PD; 
tolcapone and entacapone. Tolcapone inhibits COMT at peripheral level and to a lesser 
extent at the central level whereas entacapone acts only in the periphery.  
COMT inhibitors are effective when administered in conjunction with levodopa and 
increase interdose, trough, and mean levodopa concentrations. Administration of levodopa 
plus a COMT inhibitor results in smoother plasma levodopa levels and more continuous 
brain availability compared with levodopa alone (Muller et al, 2006). Thus, administering 
levodopa with a COMT inhibitor has the potential to deliver levodopa to the brain in a more 
predictable and stable fashion, thus decreasing the fluctuations in levodopa concentrations 
seen when standard levodopa is administered intermittently. 
Double-blind, placebo-controlled trials have demonstrated that both tolcapone and 
entacapone increase “on” time, decrease “off” time, and improve motor scores for patients 
with PD who experience motor fluctuations. Moreover, this benefit was associated with a 
reduction in the mean daily dose of levodopa (Kurth et al, 1997; Parkinson Study Group, 
1997). Benefits have been shown to persist for 3 years or longer (Larsen et al, 2003). In 
general, superior clinical benefits have been achieved with tolcapone, reflecting the 
increased level of COMT inhibition. 
Benefits with COMT inhibitors have also been observed in stable patients PD who have not 
yet begun to experience motor fluctuations (Waters et al, 1997; Olanow et al, 2004). 
There has also been interest in the potential of COMT inhibitors to reduce the risk for motor 
complications associated with standard doses of levodopa (Olanow and Stocchi, 2004). This 
is based on the concept that intermittent doses of short-acting levodopa leads to pulsatile 
stimulation of dopamine receptors and motor complications. COMT inhibitors extend the 
elimination half-life of levodopa and thus, if administered frequently enough, might 
provide continuous levodopa to the brain. Although studies in monkeys showed that 
administration of levodopa plus the COMT inhibitor entacapone reduced dyskinesias 
compared with treatment with levodopa alone (Smith et al, 2005), these results have not 
been observed in patients. Specifically, in a recent clinical trial, Stalevo Reduction in 
Dyskinesia Evaluation (STRIDE-PD), which compared the time to onset and frequency of 
dyskinesia in levodopa-naïve PD patients who were randomized to initiate levodopa 
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therapy with carbidopa/levodopa compared with carbidopa/levodopa/entacapone 
(Stalevo), was demonstrated that patients randomized to Stalevo had an increased 
frequency and a shorter time to dyskinesia than did those on standard levodopa (Stocchi et 
al, 2010). 
COMT inhibitors increase levodopa bioavailability, and hence they increase the incidence 
of dopaminergic adverse reactions, including nausea, and cardiovascular and 
neuropsychiatric complications. Diarrhoea and urine discoloration are the most 
frequently reported non-dopaminergic adverse reactions. Tolcapone can elevate liver 
transaminases, and fatal cases of liver injury are reported (Assal et al, 1998). Currently, the 
drug has been reintroduced to the market in many countries, but has been imposed strict 
safety restrictions.  
5.2.4 MAO-B inhibitors 
Selegiline and rasagiline inhibit the action MAO-B. MAO-B prevents the breakdown of 
dopamine, leading to greater dopamine availability. Mechanisms besides MAO-B inhibition 
may also contribute to the clinical effects (Olanow, 1996). Unlike selegiline, rasagiline is not 
metabolized to amphetamine, and has no sympathomimetic activity. 
Selegiline was initially approved as an adjunct to levodopa in patients with motor 
fluctuations. However, selegiline is primarily used in early disease, based on its putative 
neuroprotective effects (see section on Neuroprotection) and its capacity to provide mild 
symptomatic benefits (Parkinson Study Group 1993). When combined with levodopa, it can 
enhance dopaminergic side effects and lead to increased dyskinesia and neuropsychiatric 
problems, particularly in the elderly.  
Rasagiline has been approved for use in patients with both early and advanced PD. 
Rasagiline is an irreversible inhibitor of MAO-B. It is more potent and more selective than 
selegiline, and does not generate amphetamine or methamphetamine metabolites. TEMPO 
study, a class I study with rasagiline, showed improvement of both the total UPDRS and the 
motor subscale of the UPDRS in patients treated with rasagiline versus placebo (Parkinson 
Study Group 2002). Recently published data on long-term efficacy of rasagiline in patients 
who participated in the TEMPO study, showing maintenance of rasagiline as monotherapy 
in about half of patients after two years of follow-up (Lew et al, 2010). In ADAGIO study 
early vs delayed start rasagiline 1 or 2 mg/day were compared. The results of this study 
suggest that early treatment with rasagiline 1 mg/ day provides benefits that cannot be 
attained with later initiation of the drug, and argues for starting symptomatic treatment at 
an earlier time point than has conventionally been used (Olanow et al, 2009). The PRESTO 
(Parkinson Study Group, 2005) and LARGO (Rascol et al, 2005) study have demonstrated 
the benefit of rasagiline in patients with motor fluctuationes.  
Safinamide is a new MAO-B inhibitor that is currently being studied as a treatment for early 
and advanced PD. In addition to its MAO-B inhibitor properties, it also inhibits dopamine 
uptake, and blocks sodium channels and glutamate release. A randomized, placebo-
controlled trial of safinamide in early to midstage PD demonstrated modest 
antiparkinsonian effects, with benefits specifically noted in patients who were already 
receiving a dopamine agonist (Stocchi et al, 2004). 
MAO inhibitors are generally well tolerated. Amphetamine metabolites of selegiline may 
induce insomnia. At the daily doses currently recommended, the risk of tyramine-induced 
hypertension (the cheese effect) is low. Also this reaction has not been reported with 
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selective inhibitors of MAO-B (Heinonen EH and Myllylä, 1998). Concerns that the 
selegiline/levodopa combination increased mortality rates (Ben-Shlomo et al, 1998) have 
been allayed (Olanow et al, 1998). MAO inhibitors may also interfere with serotonin 
metabolism and induce a serotoninergic syndrome, although this reaction is rarely 
presented (Ritter and Alexander, 1997). 
5.2.5 Other antiparkinsonian drugs 
5.2.5.1 Anticholinergics 
The precise mechanism of action of anticholinergic drugs in PD is not known although are 
believed to act by correcting the disequilibrium between striatal dopamine and acetyl 
choline activity. Some anticholinergics, e.g. benzotropine, can also block dopamine uptake 
in central dopaminergic neurons. The anticholinergics used to treat PD specifically block 
muscarinic receptors. 
The use of anticholinergics has dramatically declined in the era of levodopa and dopamine 
agonists, but these agents are still occasionally used. Anticholinergic drugs are typically 
used in younger patients with PD in whom resting tremor is the dominant clinical feature 
and where cognitive function is preserved. Anticholinergic drugs are of little value in the 
treatment of other parkinsonian features such as rigidity, akinesia, gait dysfunction, or 
impaired postural reflexes (Cantello et al, 1986). Currently trihexyphenidyl is the most 
widely used of the anticholinergic drugs.  
The most commonly reported side effects are blurred vision, urinary retention, nausea, 
constipation (rarely leading to paralytic ileus), and dry mouth. The incidence of reduced 
sweating, particularly in those patients on neuroleptics, can lead to fatal heat stroke. 
Anticholinergics are contraindicated in patients with narrow-angle glaucoma, tachycardia, 
hypertrophy of the prostate, gastrointestinal obstruction, and megacolon. Impaired mental 
function (mainly immediate memory and memory acquisition) is a well-documented central 
side effect that resolves after drug withdrawal. Therefore, if dementia is present, the use of 
anticholinergics is contraindicated (Van Herwaardenet al, 1993). 
5.2.5.2 Amantadine 
Amantadine’s mechanism of action remains unclear. A blockade of N-methyl-D-aspartate 
(NMDA) glutamate receptors and an anticholinergic effect are proposed, whereas other 
evidence suggests an amphetamine-like action to release presynaptic dopamine stores 
(Kornhuber et al, 1994). 
Amantadine has been shown to improve akinesia, rigidity, and tremor in placebo-controlled 
trials when used as monotherapy or in combination with levodopa. Early studies suggested 
that benefit with amantadine is transient, but some patients enjoy more sustained benefits 
(Butzer et al, 1975; Timberlake and Vance, 1978). 
Amantadine is the only currently available agent that is capable of blocking dyskinesia 
without interfering with the parkinsonian response and has proven to be of considerable 
benefit for some patients. The utilization of amantadine, however, may be limited by its 
propensity to cause cognitive impairment, particularly in patients with advanced PD 
(Verhagen Metman et al, 1998; Metman et al, 1999). 
Side effects include confusion, hallucinations, insomnia, and nightmares. These are more 
common in older patients, but can be seen in patients of any age. Peripheral side effects 
include livedo reticularis and ankle edema, although these are rarely severe enough to limit 
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treatment. Dry mouth and blurred vision can occur and are presumed related to its 
peripheral anticholinergic effects. 
5.3 Nonmotor symptoms treatment of Parkinson's disease (Table 2) 
NMS in PD include neuropsychiatric symptoms, sleep disturbances, autonomic dysfunction, 
and pain or sensory problems. Such symptoms are a frequent accompaniment to the motor 
disability with continuing disease progression (Chaudhuri et al, 2006). Although several 
nondopaminergic systems within the brainstem and cortex are involved in PD, specific 
clinicopathological correlation for such features remains uncertain, and despite the 
increasing recognition of these problems, specific pharmacological therapies that target the 
relevant nondopaminergic neurotransmitter system are limited. 
The management of dementia in PD is a pressing problem because cognitive impairment is a 
common and important source of disability. As dementia in PD is associated with a 
cholinergic deficit, trials of the cholinesterase inhibitors donepezil and rivastigmine have 
been carried out in patients with dementia. In these studies, both rivastigmine (Emre et al, 
2004) and donepezil (Ravina et al, 2005) showed a modest but significant improvement 
compared with controls without worsening of parkinsonism. 
The cause of psychotic symptoms in PD is probably multifactorial, involving interplay 
between pathological processes and dopaminergic medications. The management of 
hallucinations and delirium in the patient with PD must begin with a pretreatment setting 
eliminating those drugs that can cause hallucinations or delusions and adjusting the dose of 
levodopa. When the adjustments fail to eliminate or sufficiently alleviate hallucinations 
and/or cannot be accomplished without inducing a meaningful deterioration in PD 
features, neuroleptic therapy should be considered. Haloperidol, perphenazine, or 
chlorpromazine are effective antipsychotics, but are not recommended for patients with PD 
because of their capacity to block striatal dopamine D2 receptors and exacerbate 
parkinsonian features. The “atypical” neuroleptics are the preferred agents to use (especially 
clozapine (Parkinson Study Group, 1999) and quetiapine (Fernandez et al, 2003)), and can 
often effectively treat hallucinations and psychosis induced by dopaminergic medications. 
They are called “atypical” because among other factors they preferentially block limbic and 
cortical dopamine receptors, but are relatively devoid of D1 and D2 receptor-blocking 
properties (Friedman and Factor, 2000). 
Anxiety and depression are extremely common in PD and frequently coexist. Both might 
respond to dopaminergic therapies, and anxiety in particular can be experienced when the 
motor effects of levodopa have worn off (ie, during an “off period). However, successful 
management of these mood disorders often requires treatments in addition to dopaminergic 
agents, which suggests that non-dopaminergic neurotransmitters are involved. The current 
management of depression and anxiety in PD involves the use of conventional treatments 
that enhance serotonergic neurotransmission, such as selective serotonin reuptake inhibitors 
(SSRIs) or tricyclic antidepressants. Although in clinical practice many patients with PD do 
experience a significant improvement in mood symptoms with these agents (whatever the 
exact mechanism of action), the true effectiveness in PD has not been established owing to 
the limited numbers of available randomised controlled trials (Weintraub et al, 2005; Chung 
et al, 2003). Some antidepressants, which are undergoing investigation for depression and 
anxiety in PD, are also selective noradrenergic reuptake inhibitors (eg, duloxetine, 
venlafaxine, and desipramine). 
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Patients with PD can experience various behavioural problems as a consequence of 
dopaminergic medications, including impulse control disorders, such as pathological 
gambling, shopping, eating, and hypersexuality,(Voon et al, 2011) and abnormal excessive 
motor behaviours ranging from purposeless fiddling to complex stereotypic activities, 
known as ȸpundingȹ(Evans et al, 2004). These problems have been particularly associated 
with dopamine agonists, but also with levodopa. The precise mechanism whereby 
dopamine agonists might induce these ICDs is not known. Treatment of each patient should 
be individualized based on the magnitude of the ICD problem and the need for 
dopaminergic drugs to control PD features. The symptoms might resolve on reducing or 
discontinuing the dopamine agonists, although they can persist in some patients 
(Mamikonyan et al, 2008). Other approaches could include trials of various psychoactive 
agents and psychosocial interventions and referring patients for appropriate counseling 
services. 
Sleep dysfunction in PD is usually manifest by difficulty in initiating sleep, fragmented 
sleep, reversal of the sleep cycle, and EDS. Sleep disturbances in PD are multifactorial and 
may be related to aging, parkinsonian motor dysfunction, dyskinesia, pain, nocturia, 
nightmares, dopaminergic and nondopaminergic medications, cognitive impairment, and a 
variety of specific sleep disorders, including restless legs syndrome (RLS), periodic limb 
movements of sleep (PLMS), RBD, and sleep apnea. Collectively, they contribute to the 
increase in daytime sleepiness that is so frequently found in patients with PD (Tandberg et 
al, 1999; Comella, 2007). Dopaminergic medications and particularly dopamine agonists can 
have a complex effect on sleep. Sometimes these medications cause insomnia or sleepiness. 
In other situations they may improve nocturnal immobility, and in this way improve the 
quality of sleep (Montastruc et al, 2001; Brodsky et al, 2003). Thus, dopaminergic 
medications can either improve or worsen sleep in patients with PD. RBD in patients with 
PD may be effectively treated with low-dose clonazepam (0.25 to 1.0 mg nightly). The wake-
promoting drug modafinil, which possibly affects histamine release in the hypothalamus, is 
currently used as an option to treat excessive daytime sleepiness in patients with PD 
(Morgenthaler et al, 2007). Is currently being assessed two other drugs (the BF 2.649 a 
selective histamine H3 inverse agonist and the caffeine, a non-selective adenosine 
antagonist) in the treatment of EDS in PD patients.  
Drugs currently used to treat orthostatic hypotension in PD include midodrine, a 
sympathomimetic, and fludrocortisone, a mineralocorticoid. Supine hypertension is a 
potential side-effect of both of these approaches. The acetylcholinesterase inhibitor 
pyridostigmine bromide has been suggested to reduce orthostatic hypotension with less 
effect on supine hypertension, although evidence is limited (Low and Singer, 2008). L-threo-
3, 4- dihydroxyphenylserine is a synthetic amino acid precursor of noradrenaline that is 
available for freezing of gait in PD and orthostatic hypotension in autonomic failure 
(Mathias et al, 2001). However, few randomised controlled trials few randomised controlled 
trials (RCTs) of treatment for orthostatic hypotension have been undertaken specifically in 
PD, but rather have involved mixed populations of patients including multiple system 
atrophy, in which the pathophysiology of orthostatic hypotension is different. Thus, the true 
efficacy of treatments for orthostatic hypotension in PD remains unclear. 
Urinary symptoms can be troublesome in advanced PD. Current treatments are drugs for 
overactive bladder symptoms, such as the muscarinic antagonists oxybutynin and 
tolterodine. However, such drugs are typically poorly tolerated in patients with advanced 
PD due to central and peripheral anticholinergic side-effects. Another muscarinic 
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antagonist, trospium chloride, has potentially fewer central side-effects due to poor 
penetration of the blood–brain barrier, and is effective for treating overactive bladder 
symptoms (Staskin, 2006). 
Postural instability is a late complication of PD which can lead to a mounting fear of falls 
with increasing immobilisation and dependency. Most falls in patients with PD occur in a 
forward or sideways direction and are due to turning difficulties, gait and postural 
asymmetries, problems with sensorimotor integration, difficulties with multitasking, failure 
of compensatory stepping, and orthostatic myoclonus (Bloem et al, 2004). Skilled physical 
therapy with cueing to improve gait, cognitive therapy to improve transfers, exercises to 
improve balance, and training to build up muscle power and increase joint mobility, is 
efficacious (Keus et al, 2007). Regular physical and mental exercise should be encouraged at 
all stages of the disease. Benzodiazepines should be avoided wherever possible because they 
increase the risk of falling. 
 
Insomnia 
Adjust dopaminergic drugs, sleep hygiene techniques or clonazepam 
Depression 
Serotonin and noradrenergic reuptake inhibitors or tricyclic antidepressants  
Rapid eye movement behaviour disorders 
Adjust Parkinson’s disease drugs or clonazepam 
Fatigue 
Amantidine or selegiline 
Day time sleepiness 
Modafinil 
Psychosis and hallucinations 
Adjust Parkinson’s disease drugs or antipsychotic (clozapine, quetiapine) 
Constipation 
Osmotic laxatives (macrogol) 
Urinary urgency 
Check drugs, anticholinergic bladder stabilisers, and desmopressin for nocturia 
Impotence 
Sildenafil, tadalafil, and vardenafil 
Pain 
Adjust Parkinson’s disease drugs and muscle relaxants 
Restless legs 
Dopamine agonists 
Orthostatic hypotension 
Adjust Parkinson’s disease drugs; increase water and salt intake; fludrocortisone, 
ephedrine, or midodrine 
Drooling 
0-5% atropine eye drops sublingually, scopoderm patch, or botulinum toxin injections 
into salivary glands 
Excessive sweating 
Adjust Parkinson’s disease drugs, propantheline, propranolol, or topical aluminium 
creams 
Table 2. Treatment of Non motor symptoms of PD 
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6. Surgical procedure for the treatment of Parkinson's disease  
The capacity of surgical therapies to provide benefit for patients with PD who can no longer 
be satisfactorily controlled with medical therapies due to motor complications has been a 
major advance in the modern treatment of PD (Hallett and Litvan, 2000). Surgical therapies 
have historically used ablative procedures (e.g., chemical, radiofrequency, or thermal 
lesions) to make a destructive lesion in overactive or abnormally firing brain targets. 
However, ablative procedures are associated with the risk of inducing damage to 
neighboring structures with consequent neurologic dysfunction. The introduction in 1987 of 
high-frequency deep brain stimulation (DBS) procedures in PD has resolved many of these 
issues. High frequency stimulation of specific brain targets induces functional benefits that 
simulate the effects of a destructive lesion, but without the need for making a destructive 
brain lesion. DBS is performed by implanting an electrode with four contacts into a target 
site within the brain and connecting it to a pulse generator placed subcutaneously over the 
chest or abdomen wall. Stimulator settings can be adjusted periodically with respect to 
electrode configuration, voltage, frequency, and pulse width (Bergman et al, 1990; Olanow 
et al, 2000).  
The mechanism of action of high-frequency DBS is still not clear, even more than 21 years 
after its introduction. The mechanism is believed to be independent of the target, because 
DBS mimics the effects of ablation in all targets used to date, but its effects depend on 
stimulation rather than on the creation of a lesion. 
Patients who are thought to benefit from DBS are those affected by clinically diagnosed 
idiopathic PD, in whom the cardinal symptoms of the disease— bradykinesia, rigidity, 
and tremor— are likely to be significantly improved (Krack et al, 2003; Deuschl et al, 
2006). Those who show improvement with the optimum adjustment of anti-PD drugs or 
suprathreshold levodopa dose (300 mg per dose) are highly likely to show a similar 
improvement after optimum placement of the electrodes (Charles et al, 2002). Higher 
baseline scores on section III (motor) of the unified PD rating scale (UPDRS) and higher 
baseline levodopa responsiveness are independent predictors of greater change in motor 
score after surgery. Midline symptoms, dysautonomic symptoms, and gait disturbance 
unresponsive to levodopa (ie, freezing) are only slightly improved, if at all (Xie et al, 
2001). 
The different surgical targets exist in the treatment of PDare as follows: - Ventral 
intermediate (VIM) nucleus of the thalamus: stimulation procedures in this target provide 
potent antitremor (Narabayashi, 1989) and antidyskinesia (Narabayashi et al, 1984) effect in 
PD. However, the thalamus is rarely selected as a target site today because similar benefits 
can be obtained with other targets that are associated with more widespread 
antiparkinsonian effects. Subthalamic nucleus (STN) or internal segment of the globus 
pallidus (GPi)—physiologic and metabolic studies indicate that neurons in both the STN 
and GPi are overactive in PD (Crossman et al, 1985; Mitchell et al, 1989), and that lesions of 
these structures provide antiparkinsonian benefits in animal models of PD (Bergman et al, 
1990; Brotchie et al, 1991; Guridi et al, 1994;). Both ablation and high frequency stimulation 
of these targets have been shown to provide antiparkinsonian benefits as well as a profound 
reduction in dyskinesia (especially GPi) in patients with PD. Although the STN is currently 
the preferred surgical target in most centers, there is no conclusive data indicating that 
comparable results cannot be obtained with stimulation of the GPi (Follet et al, 2010). 
Patients undergoing subthalamic stimulation required a lower dose of dopaminergic agents 
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than did those undergoing pallidal stimulation.- Pedunculopontine nucleus (PPN)—the 
PPN is a diffuse nucleus that extends throughout the upper brainstem. Stimulation and 
lesions in the PPN influence locomotion, and for this reason it has been referred to as the 
mesencephalic locomotor center (Pahapill and Lozano, 2000). Preliminary studies suggest 
that stimulation of the PPN may provide locomotor benefits for patients with PD (Stefani et 
al, 2007). DBS of the PPN is being actively investigated. 
Side effects of DBS can be related to the surgical procedure, the device, or to the stimulation. 
There is a risk of hemorrhage and damage to neighboring brain structures, although risks 
are less than are seen with ablative procedures, particularly when performed bilaterally 
(Hallett and Litvan, 2000). Complications associated with the device can be related to 
infection or mechanical problems (e.g., lead fracture, movement of the electrode, skin 
erosion), and may require lead removal or reimplantation. Side effects related to stimulation 
are generally transient and may be controlled by adjusting the stimulation variables. The 
battery must be periodically replaced. 
7. Recommendations for the management of Parkinson's disease  
The optimal time frame for onset of therapy has not been clearly defined. Once parkinsonian 
signs start to have an impact on the patient’s life, initiation of treatment is recommended. 
For each patient, the choice between the numerous effective drugs available is based in 
several factors. These factors include considerations related to the drug (efficacy for 
symptomatic control of parkinsonism/prevention of motor complications, safety, 
practicality, costs, etc.), and the patient (symptoms, age, needs, expectations, experience, co-
morbidity, socioeconomic level, etc.).  
Currently, there is no uniform proposal on initiating symptomatic medication for PD. In the 
past, levodopa was traditionally used to initiate therapy for PD because it was the most 
effective symptomatic agent, and levodopa is still commonly used as initial therapy by some 
physicians. Today, many movement disorder neurologists have elected to initiate 
symptomatic therapy with a dopamine agonist in appropriate patients, and to supplement 
with levodopa when satisfactory control cannot be attained with dopamine agonist 
monotherapy. This treatment philosophy is based on the body of laboratory and clinical 
information indicating that dopamine agonists are associated with a reduced risk of 
inducing motor complications compared with levodopa. Dopamine agonist use as as initial 
therapy because they delay the time until levodopa is required and permit use of lower 
doses of levodopa. To begin with levodopa is the preferred treatment for patients with PD 
with cognitive impairment, the elderly who have a reduced propensity to develop motor 
complications, and patients suspected of having an atypical parkinsonism who are 
undergoing a trial of dopaminergic therapy. 
MAO-B inhibitors such as selegiline and rasagiline provide another therapeutic option in 
early disease. MAO-B inhibitors have been shown to provide modest antiparkinsonian 
effects when used as monotherapy and also delay the need for levodopa. The symptomatic 
effect is more modest than that of levodopa and (probably) dopamine agonists, but they are 
easy to administer (one dose, once daily, no titration). Furthermore the TEMPO and the 
ADAGIO studies suggest that early treatment with rasagiline provides benefits that cannot 
be attained with later introduction of the same medication (Parkinson Study Group, 2002; 
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Olanow et al, 2009). Although this does not establish neuroprotection and long-term studies 
are required to determine the effect of the drug on cumulative disability in the long run, it 
does indicate that earlier treatment with rasagiline may provide a better outcome, at least at 
the 18-month time point. For these reasons, many physicians now choose to initiate therapy 
in patients with early PD with an MAO-B inhibitor. 
There may be advantages to initiating therapy in patients with early PD with both an MAO-
B inhibitor and a dopamine agonist (not at the same time) to enhance clinical benefits and 
further delay the need for levodopa. However, there have been no studies as yet examining 
the effects of combining an MAO-B inhibitor with a dopamine agonist on the need for 
levodopa and the risk of inducing dyskinesia. However, subset analyses in studies testing 
rasagiline in advanced patients (Parkinson Study Group, 2005; Rascol et al, 2005) and 
preliminary studies with a new MAO-B inhibitor safinamide, (Stocchi et al, 2004) suggest 
that adding an MAO-B inhibitor to a dopamine agonist improves UPDRS scores. 
Amantadine or anticholinergics are not routinely prescribed in patients with early PD, 
although some movement disorder specialists might use anticholinergics if tremor is the 
predominant feature in young patient with PD. 
There are a variety of ways to enhance motor response in patients who experience 
suboptimal motor control with dopamine agonist or levodopa monotherapy. The simplest 
approach is to gradually raise the dose of the dopaminergic agent. However, high doses of 
dopamine agonists can be associated with neuropsychiatric side effects, sedation and ICDs. 
If patients cannot be satisfactorily controlled on an agonist, then levodopa should be added. 
If the patient is receiving levodopa monotherapy, increased doses might be effective. Higher 
doses are associated with an increased risk of motor complications, but may be justified if 
required to provide a satisfactory clinical response. The addition of a dopamine agonist may 
enhance benefit without increasing the risk of motor complications. COMT and/or MAO-B 
inhibitors may also be useful in managing patients with a suboptimal clinical response. The 
use of a subcutaneous apomorphine penject as a rescue device for unpredictable refractory 
off periods can also be helpful in some instances, and its fast action helps to restore 
confidence in patients becoming insecure about leaving home (Ostergaard et al, 1995). 
Despite adjustments of the timing and dose frequency of levodopa, motor fluctuations and 
dyskinesias can mark the long-term therapeutic benefit. Amantadine is an effective anti-
dyskinetic agent in some patients. Subcutaneous waking day apomorphine pump is a highly 
effective treatment for refractory motor fluctuations. Orally administered anti-parkinsonian 
medication should be adjusted obtain thebest results for dyskinesia reduction and off 
periods. Enteric administration of a soluble formulation of levodopa (Duodopa) through 
gastro-jejunostomy is another highly effective medical option for patients who failed to, or 
are reluctant to, try the apomorphine pump. Infusion therapies is based on the principle that 
continuous infusion of a dopaminergic agent provides more constant and physiologic 
activation of striatal dopamine receptors than is accomplished with intermittent 
administration of the same drug, and thereby reduces the risk of motor complications. 
Continuous infusion of either levodopa or apomorphine has been tested in patients with 
advanced PD and consistently been reported to reduce the frequency of motor 
complications (Manson et al, 2002; Antonini et al, 2007). Sustained improvement in motor 
performance with a great reduction in drug-induced involuntary movements can also be 
achieved by functional neurosurgery with bilateral deep brain stimulation of the STN or 
GPi. 
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8. Experimental approaches  
Cell-based therapies have been studied based on the notion that transplantation of 
dopaminergic cells could replace dopamine neurons, which degenerate in PD, and restore 
dopaminergic function in a more physiologic manner than can be achieved with oral 
therapies (Lindvall and Bjo¨rklund, 2004). Fetal nigral transplantation has been the best 
studied of these approaches to date. Numerous laboratory studies have demonstrated that 
embryonic dopaminergic neurons implanted into the denervated striatum can survive, 
extend axons, provide organotypic innervations of the striatum, produce dopamine, and 
provide behavioral benefits in the 6-OHDA rodent and MPTP-monkey (Olanow et al, 1996). 
These studies have served as the basis for initiating clinical trials in patients with PD. To 
date, there is no universal agreement on the optimal transplant protocol. Open-label clinical 
trials using a variety of different transplant regimens produced variable clinical results. 
Various types of cells have been used (adrenal gland, mesencephalic fetal grafts, and more 
recently, epithelial retinal cells). Stem cells are also being investigated, which might be better 
tolerated immunologically, but raise their own (oncological) problems. Despite the elegance 
of this approach, it is still experimental and is not currently available to patients (Morizane 
et al, 2008). Intrastriatal carotid body (CB) transplants have been assayed in animal models 
of PD to test whether they increase the striatal dopamine levels and/or exert a 
neuroprotective action on the nigrostriatal pathway. Currently it being studied the in vitro 
formation of new CB tissue derived from adult CB stem cells, given the limitations of 
previous studies have been presented with autotransplantation of CB in patients with PD 
(López-Barneo et al, 2009). 
Gene delivery approaches are also being actively investigated as a possible treatment for 
PD. In this technology, viruses are used as vectors to introduce the DNA of a desired protein 
into the genome of cells within a specific brain target. Furthermore, promoters can ensure 
that the virus vector infects specific brain cells (e.g., TH promoter targets dopamine cells). 
This sequence can thus potentially result in continuous production of the desired 
therapeutic protein in the desired target region of the brain (Dass et al, 2006). Most human 
studies have used the adeno-associated virus serotype 2 (AAV-2) as the vector, as AAV-2 
does not induce an immune response and permits long-term expression of the transgene. No 
clinically significant or unanticipated adverse events have been encountered in any of the 
gene therapy studies performed to date (Svendsen, 2007). Different gene therapy 
approaches are currently being tested in PD, e.g trophic factors such as glial-derived nerve 
factor (Lang et al, 2006) or neurturin (Marks et al, 2010).  
9. Conclusions 
The current knowledge of the disease continues to evolve and be challenged by scientific 
discovery. Further research on the function of the proteins identified by the susceptibility 
genes, the interplay of the disease process with normal ageing, and the nature of 
environmental triggers that unmask the disease process will be needed if we are to develop 
reliable biomarkers and a cure for this disabling movement disorder. Although it is 
producing significant progress in new therapeutic options important unmet medical needs 
remain, and even more effective therapeutic interventions are required for the successful 
management of the patient with PD. Many such agents are now in development. However, 
future strategies need to focus on more selective targeting of subtypes of neurotransmitter 
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receptors to reduce side effects and optimise benefit. Finally, the development of 
neuroprotective agents in PD has to date focused on preventing dopamine cell loss. 
However, to be optimally effective, such therapies will also need to target nondopamine 
cells involved in the multisystem disease process. 
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